PN-235 (JNJ-77242113) now expected to advance into multiple Phase 2 clinical studies in 2022, for indications including psoriasis and inflammatory bowel diseases NEWARK, Calif., Dec. 2, 2021 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results